Novartis will no longer invest in pharmaceutical research and development in India after the Supreme Court refused to grant patent protection on the company's cancer drug Glivec, says Ranjit Shahani, vice chairman and managing director of Novartis India. Other drugmakers probably will do the same, Shahani says.

Full Story:

Related Summaries